Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nakissa Sadrieh

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Regulatory Toxicology and Pharmacology : RTP|May 7, 2026
FDA CDER analysis of non-human primate (NHP) data in monoclonal antibody (mAb) development to support the streamlining of nonclinical safety studiesYanning Hao, Nakissa Sadrieh
Regulatory Toxicology and Pharmacology : RTP|December 8, 2025
A CDER perspective: Landscape of New Approach Methodologies (NAMs) submitted in drug development programsTyna Dao, Nakissa Sadrieh
Methods in Molecular Biology (Clifton, N.J.)|December 1, 2010
Considerations when submitting nanotherapeutics to FDA/CDER for regulatory reviewKatherine Tyner, Nakissa Sadrieh
Critical Reviews in Toxicology|March 23, 2017
Skin sensitizers in cosmetics and beyond: potential multiple mechanisms of action and importance of T-cell assays for in vitro screeningStanislav Vukmanović, Nakissa Sadrieh
Advanced Drug Delivery Reviews|April 25, 2009
Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugsBanu S Zolnik, Nakissa Sadrieh
Therapeutic Delivery|July 21, 2012
Nanotechnology and therapeutic delivery: a drug regulation perspectiveNakissa Sadrieh, Katherine M Tyner
Cells|June 10, 2023
Microphysiological Models for Mechanistic-Based Prediction of Idiosyncratic DILISydney Stern, Hongbing Wang, Nakissa Sadrieh
Toxicological Sciences : an Official Journal of the Society of Toxicology|May 9, 2025
An FDA/CDER nonclinical perspective on the use of hiPSC-CM data for cardiovascular safety assessment and regulatory decisionsNatalie E Simpson, Todd Bourcier, Nakissa Sadrieh
The AAPS Journal|July 23, 2013
Impact of osmotically active excipients on bioavailability and bioequivalence of BCS class III drugsMei-Ling Chen, Nakissa Sadrieh, Lawrence Yu
Proteomics. Clinical Applications|December 8, 2010
Profiling of rat urinary proteomic patterns associated with drug-induced nephrotoxicity using CE coupled with MS as a potential model for detection of drug-induced adverse effectsHarald Mischak, Parvaneh Espandiari, Nakissa Sadrieh, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Regulatory Toxicology and Pharmacology : RTP|May 7, 2026
FDA CDER analysis of non-human primate (NHP) data in monoclonal antibody (mAb) development to support the streamlining of nonclinical safety studiesYanning Hao, Nakissa Sadrieh
Regulatory Toxicology and Pharmacology : RTP|December 8, 2025
A CDER perspective: Landscape of New Approach Methodologies (NAMs) submitted in drug development programsTyna Dao, Nakissa Sadrieh
Methods in Molecular Biology (Clifton, N.J.)|December 1, 2010
Considerations when submitting nanotherapeutics to FDA/CDER for regulatory reviewKatherine Tyner, Nakissa Sadrieh
Critical Reviews in Toxicology|March 23, 2017
Skin sensitizers in cosmetics and beyond: potential multiple mechanisms of action and importance of T-cell assays for in vitro screeningStanislav Vukmanović, Nakissa Sadrieh
Advanced Drug Delivery Reviews|April 25, 2009
Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugsBanu S Zolnik, Nakissa Sadrieh
Therapeutic Delivery|July 21, 2012
Nanotechnology and therapeutic delivery: a drug regulation perspectiveNakissa Sadrieh, Katherine M Tyner
Cells|June 10, 2023
Microphysiological Models for Mechanistic-Based Prediction of Idiosyncratic DILISydney Stern, Hongbing Wang, Nakissa Sadrieh
Toxicological Sciences : an Official Journal of the Society of Toxicology|May 9, 2025
An FDA/CDER nonclinical perspective on the use of hiPSC-CM data for cardiovascular safety assessment and regulatory decisionsNatalie E Simpson, Todd Bourcier, Nakissa Sadrieh
The AAPS Journal|July 23, 2013
Impact of osmotically active excipients on bioavailability and bioequivalence of BCS class III drugsMei-Ling Chen, Nakissa Sadrieh, Lawrence Yu
Proteomics. Clinical Applications|December 8, 2010
Profiling of rat urinary proteomic patterns associated with drug-induced nephrotoxicity using CE coupled with MS as a potential model for detection of drug-induced adverse effectsHarald Mischak, Parvaneh Espandiari, Nakissa Sadrieh, et al.
Pageof 5